Evidence map›Paper›PMID 37672348›Full record

ReviewACS synthetic biology2023

Making the Next Generation of Therapeutics: mRNA Meets Synthetic Biology.

Ahmet Hınçer, Recep Erdem Ahan, Ebru Aras, Urartu Özgür Şafak Şeker

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in ACS synthetic biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ahmet HınçerUNAM - Institute of Materials Science and Nanotechnology, National Nanotechnology Research Center, Bilkent University, Ankara 06800, Turkey.
Recep Erdem AhanUNAM - Institute of Materials Science and Nanotechnology, National Nanotechnology Research Center, Bilkent University, Ankara 06800, Turkey.
Ebru ArasUNAM - Institute of Materials Science and Nanotechnology, National Nanotechnology Research Center, Bilkent University, Ankara 06800, Turkey.
Urartu Özgür Şafak ŞekerUNAM - Institute of Materials Science and Nanotechnology, National Nanotechnology Research Center, Bilkent University, Ankara 06800, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of mRNA-based therapeutics centers around the natural functioning of mRNA molecules to provide the genetic information required for protein translation. To improve the efficacy of these therapeutics and minimize side effects, researchers can focus on the features of mRNA itself or the properties of the delivery agent to achieve the desired response. The tools considered for mRNA manipulation can be improved in terms of targetability, tunability, and translatability to medicine. While ongoing studies are dedicated to improving conventional approaches, innovative approaches can also be considered to unleash the full potential of mRNA-based therapeutics. Here, we discuss the opportunities that emerged from introducing synthetic biology to mRNA therapeutics. It includes a discussion of modular self-assembled mRNA nanoparticles, logic gates on a single mRNA molecule, and other possibilities.

Indexed as

NanoparticlesSynthetic BiologyHumansProtein BiosynthesisResearch PersonnelRNA, MessengerRNA, Messengerlogic gatesmRNA-based therapeuticsmRNA vaccinesself-assembled nanoparticlessynthetic biology

Identifiers

PMID37672348
PMCPMC10510722

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.